Jeffrey Kane
Neurology with Special Qualifications in Child Neurology · Cedar Park, TXNPI 1851343271
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,217 and has fallen 98.6% since, to $18 in 2024.
Across 155 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Greenwich Biosciences, Inc.$360
- Sunovion Pharmaceuticals Inc.$332
- Supernus Pharmaceuticals, Inc.$246
- UCB, Inc.$231
- Aquestive Therapeutics, Inc.$204
- Takeda Pharmaceuticals U.S.A., Inc.$168
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,628100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Greenwich Biosciences, Inc. | 16 | $360 |
| Sunovion Pharmaceuticals Inc. | 24 | $332 |
| Supernus Pharmaceuticals, Inc. | 21 | $246 |
| UCB, Inc. | 10 | $231 |
| Aquestive Therapeutics, Inc. | 11 | $204 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $168 |
| Tris Pharma Inc | 9 | $139 |
| Eisai Inc. | 5 | $109 |
| Jazz Pharmaceuticals Inc. | 3 | $80 |
| Upsher-smith Laboratories LLC | 3 | $66 |
| Corium, LLC | 3 | $58 |
| Biogen | 4 | $57 |
| Zogenix Inc. | 3 | $57 |
| PTC Therapeutics, Inc. | 2 | $51 |
| Ironshore Pharmaceuticals Inc. | 3 | $49 |
| Antares Pharma, Inc. | 2 | $39 |
| Shire North American Group Inc | 2 | $35 |
| SK Life Science, Inc. | 1 | $34 |
| Novartis | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Amneal Pharmaceuticals LLC | 2 | $27 |
| Neos Therapeutics, LP | 2 | $27 |
| Adlon Therapeutics L.p. | 1 | $24 |
| Saol Therapeutics Inc. | 1 | $23 |
| Itamar Medical Inc | 1 | $21 |
| Travere Therapeutics, Inc. | 2 | $20 |
| Neurelis, Inc. | 1 | $20 |
| Abbott | 1 | $18 |
| Livanova USA, Inc. | 1 | $16 |
| AbbVie | 1 | $16 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
| Nobelpharma America, LLC | 1 | $12 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
How this compares
$2,641 in reported general payments places this provider in the 65th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Other neurology with special qualifications in child neurology in Cedar Park
- Lindsay EltonCedar Park$8K
- Ryan BoeckCedar Park$6K
- Riddhiben PatelCedar Park$3K
- Roy EltermanDallas$5.9M
- Huda ZoghbiHouston$5.5M
- Diana CastroDenton$343K
- Shade MoodyHouston$194K
- Mary Kay KoenigHouston$171K
- Michael PerryFort Worth$162K
- Raphael SchiffmannDallas$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.